Introduction
The high-capacity adenoviral (HC-Ad) vector devoid of all viral genes is a promising gene transfer vehicle due to its lower immunogenicity, lower cytotoxicity and higher transgene capacity compared to the first-generation adenoviral (Ad) vector.
1,2 HC-Ad vectors expressing full-length dystrophin have the potential to restore normal biochemical and functional parameters to dystrophin-deficient skeletal muscle, as has been shown in gene transfer studies using the mdx mouse, a dystrophindeficient mouse model for Duchenne muscular dystrophy (DMD). 3, 4 Despite these promising advances in animal models of DMD, there remain limitations that currently preclude human clinical trials with HC-Ad vectors in DMD patients. We previously reported that immune responses to Ad capsid proteins and dystrophin in adult mdx mice given an HC-Ad vector expressing dystrophin were associated with significant loss of recombinant dystrophin expression within 8 weeks. 5 Another study in which dystrophin was delivered to mdx mouse muscle by intramuscular injection of normal myoblasts demonstrated a cytotoxic T lymphocyte (CTL) response against dystrophin. 6 In addition, even state-ofthe-art vector production systems have not completely eliminated helper virus contamination from HC-Ad vector preparations. Therefore, the inhibition of immune responses is likely to be necessary to achieve long-term expression of dystrophin by gene therapy.
Costimulatory molecules, which are expressed on T cells, B cells and antigen-presenting cells (APCs), play an important role in inducing antigen-specific cellular and humoral immune responses. The interaction of B7 on an APC with CD28 on a T cell forms an essential costimulatory pathway for the activation of CD8 + and CD4 + T cells that have engaged MHC-presented antigen peptide on APCs with their T-cell receptor. 7 CTLA4 is expressed on activated T cells and its upregulation in response to T-cell activation limits the extent of T-cell activation and CTL production by decreasing costimulation mediated by the CD28/B7 pathway. 8 The soluble fusion protein CTLA4Ig is a therapeutic molecule that binds to B7 on APCs and thereby interferes with the costimulatory pathway of T-cell activation. A number of studies showed effective immunosuppression by CTLA4Ig protein in rodent models of autoimmune disorders and transplantation of allografts. [9] [10] [11] Further studies demonstrated a beneficial effect of CTLA4Ig, delivered either as a protein or as a gene vector, on viral vector-mediated gene transfer to the lung or liver. [12] [13] [14] [15] [16] [17] CTLA4Ig has also been used for immunosuppression coupled with first-generation Ad vector gene delivery to skeletal muscle. A study by Guibinga et al 18 showed that recombinant CTLA4Ig protein in combination with the immunosuppressant drug FK506 improved the longevity of dystrophin gene expression delivered by a firstgeneration Ad vector to mdx skeletal muscle. Another study combined CTLA4Ig protein with a CD4-depleting antibody to stabilize b-galactosidase (b-gal) expression from a first-generation Ad vector delivered to skeletal muscle. 19 Our previous muscle gene transfer studies demonstrated proof-of-principle of the benefit of CTLA4Ig expression from an HC-Ad vector as an adjunct to muscle gene transfer by (1) prolongation of expression from a codelivered Ad vector carrying the enhanced green fluorescent protein (EGFP) and (2) successful vector readministration. 20 We show here the development of new HC-Ad vectors to benefit therapeutic gene delivery of the full-length murine dystrophin cDNA in vivo in the mdx mouse model of dystrophin-deficient muscular dystrophy. Furthermore, we show the application of HC-Ad vectormediated immune suppression using CTLA4Ig to improve dystrophin gene delivery in this disease model.
Results

Generation of a recombinant HC-Ad vectors encoding full-length dystrophin
Schematic representations of the genomes and construction of HC-Ad vectors used in this study are shown in Figure 1 . The plasmid for AdmDys, pSTK122, was generated by cloning the full-length murine dystrophin cDNA and SV40 polyadenylation signal driven by the murine muscle creatine kinase (MCK) promoter into an HC-Ad backbone plasmid with left and right inverted terminal repeats (ITRs), bacterial plasmid sequences flanked by PmeI sites, and 8.4 kb of HPRT 'stuffer' DNA. Cloning details are presented in Materials and methods. The PmeI-digested, linearized vector DNA was transfected into 293Cre4 packaging cells that were subsequently infected with helper virus, AdLC8cluc to rescue and propagate AdmDys vector. Correct DNA structure was confirmed by restriction mapping and Southern blot analysis (data not shown).
The HC-Ad vector carrying both murine dystrophin and CTLA4Ig expression cassettes, AdmCTLA4Ig/ mDys, was generated by homologous recombination of two DNA fragments in packaging cells. Cloning details for each fragment are presented in Materials and methods. The 5 0 fragment contained the left ITR, the human cytomegalovirus immediate-early promoter (HCMV)-driven murine CTLA4Ig/poly(A) expression cassette and 6.1 kb of HPRT 'stuffer' DNA. The 3 0 fragment contained the same 6.1 kb of HPRT 'stuffer' DNA, the MCK-driven dystrophin/poly(A) expression cassette and the right ITR. The 5 0 and 3 0 vector DNA fragments were simultaneously transfected into 293Cre4 packaging cells with helper virus AdLC8cluc infection to rescue HC-Ad vector AdmCTLA4Ig/mDys. Vector DNA structure was confirmed by restriction mapping and Southern blot analysis (data not shown). The construction and rescue of HC-Ad vectors, AdmCTLA4Ig and AdFK0, were previously described. 20 The concentration of HC-Ad vector and helper virus AdLC8cluc in each purified vector stock was measured by real-time PCR to determine vector genome copies (gc) per ml. The concentration of each vector stock and percent contamination by helper virus are shown in Table 1 .
Gene expression in murine mdx myoblasts
To determine expression levels of murine CTLA4Ig and murine dystrophin produced by the recombinant Figure 3 ). The higher expression of mCTLA4Ig in mice injected with AdmCTLA4Ig/mDys as compared to the group receiving AdmCTLA4Ig likely relates to the administration amount of vector carrying CTLA4Ig. In the coadministered group, the amount of HC-Ad vector carrying mCTLA4Ig was 10-fold less than in the AdmCTLA4Ig/mDys group to keep the total viral vector loads of the groups comparable. The serum mCTLA4Ig level was baseline at each time point for the control group that received 3 Â 10 9 gc of AdmDys and 3 Â 10 8 gc of AdFK0.
Dystrophin expression from HC-Ad vectors in the mdx mouse model
To assess the effect of mCTLA4Ig delivered by gene transfer on the duration of HC-Ad vector-delivered recombinant mouse dystrophin expression in the mdx mouse model, we compared two experimental groups, one that received a coinjection of 3 Â 10 9 gc of AdmDys and 3 Â 10 8 gc of AdmCTLA4Ig and one that received a single injection of 3 Â 10 9 gc of AdmCTLA4Ig/mDys to a control group that received a coinjection of 3 Â 10 9 gc of AdmDys and 3 Â 10 8 gc of AdFK0. In all three groups, recombinant dystrophin localized to the periphery of muscle fibers (Figure 4 ). At 2 weeks postinfection, we observed 210722 (n ¼ 4 injected TA muscles from two mice) and 108725 (n ¼ 4 injected TA muscles from two mice) dystrophin-expressing fibers per cross-section from AdmDys and AdmCTLA4Ig coinjected mice and AdmCTLA4Ig/mDys-injected mice, respectively. The therapeutic benefit of mCTLA4Ig was revealed by the observation of stable levels of dystrophin-positive fibers that remained in the coinjected AdmCTLA4Ig and AdmDys group (183726 fibers/section, n ¼ 8 injected Dystrophin and CTLA4Ig gene transfer to muscle Z Jiang et al TA muscles from four mice) and the AdmCTLA4Ig/ mDys group (95710 fibers/section, n ¼ 8 injected TA muscles from four mice). In contrast, at the end of the experiment (8 weeks), the average number of dystrophin-positive muscle fibers decreased significantly in the control group coinjected with AdmDys and AdFK0 (90717 fibers/section, n ¼ 8 injected TA muscles from four mice), as compared to that at 2 weeks postadministration (203737 fibers/section, n ¼ 4 injected TA muscles from two mice). The background dystrophin expression in noninjected mdx mouse muscle was approximately 2-5 revertant fibers per cross-section. 21 
Splenocyte cytokine expression after HC-Ad vector dystrophin delivery
The in vitro production of murine IFN-g, IL-2, IL-4 and IL-6 cytokines by splenocytes isolated from treated mice was analyzed by ELISA to investigate the cellular immune response against Ad proteins. Coadministration of 3 Â 10 9 gc of AdmDys and 3 Â 10 8 gc of empty vector, AdFK0, into TA muscle of mdx mice resulted in the production of IFN-g (198752 pg/ml), IL-2 (67.375.8 pg/ ml), IL-4 (1.070.1 pg/ml) and IL-6 (91.878.9 pg/ml) by cultured splenocytes collected 8 weeks postadministration, after stimulation in vitro with heat-inactivated Ad vector ( Figure 5 ). In the 3 Â 10 9 gc of AdmDys and 3 Â 10 8 gc of AdmCTLA4Ig coinjected group, the levels of IFN-g (10.972.2 pg/ml), IL-2 (27.271.9 pg/ml), IL-4 (0.670.1 pg/ml) and IL-6 (49.773.6 pg/ml) were significantly lower than those in the control group. The production of all cytokines by the 3 Â 10 9 gc of AdmCTLA4Ig/mDys injected group was similar to the AdmDys and AdmCTLA4Ig coinjected group ( Figure 5 ). Cytokines were not produced by unstimulated splenocytes in vitro from mice of the three groups (data not shown), indicating that Ad vector capsid proteins specifically induced the splenocyte production of the measured cytokines.
CTL response to HC-Ad vector dystrophin delivery
In preliminary studies, we observed cellular infiltrates, composed of both CD4 + and CD8 + T cells, that were greater in mdx muscle coinjected with 3 Â 10 9 gc of AdmDys and 3 Â 10 8 gc of AdFK0 than in mdx muscle coinjected with 3 Â 10 9 gc of AdmDys and 3 Â 10 8 gc of AdmCTLA4Ig 2 weeks after vector administration. By 8 weeks after vector administration, CD4 + and CD8 + T cells were not detected in either group, suggesting that the T-cell infiltrate is largely due to the delivery inoculum of HC-Ad vector (data not shown). To further explore the T-cell response induced by Ad vector-mediated An asterisk (*) marks statistically significant changes in cytokine production compared to the AdFK0 and AdmDys coinjected group in which the adjusted P-value is o0.05 as determined by one-way ANOVA followed by Bonferroni correction for multiple comparisons.
Dystrophin and CTLA4Ig gene transfer to muscle Z Jiang et al dystrophin delivery to skeletal muscle, we looked for the formation of Ad vector-specific and dystrophin-specific CTL lysis of myotubes in vitro by splenocytes collected 2 weeks after gene delivery of AdmCTLA4Ig and AdmDys to one group and, AdFK0 and AdmDys to a second group (3 Â 10 9 gc of each vector was injected in the left TA; splenocytes from each group (n ¼ 4 within each group) were pooled). We found Ad-specific CTLs in the negative control group, but CTLs were significantly suppressed in the group receiving a coadministration of AdmCTLA4Ig (Figure 6a ). At this 2-week time point, we did not see the development of dystrophin-specific CTLs in either group (Figure 6b ). 
Humoral immune responses to HC-
Ad vector dystrophin delivery Serum from experimental mice was collected at 2, 4, 6 and 8 weeks after vector administration. The titer of neutralizing antibody against Ad vector was determined by the ability of experimental mouse serum to inhibit Ad vector infection of 293 cells. Anti-Ad neutralizing antibody was found in the control group that received a coinjection of 3 Â 10 9 gc of AdmDys and 3 Â 10 8 gc of AdFK0 and both experimental groups, one that received a coinjection of 3 Â 10
Discussion
In this report, we describe the generation of two new HC-Ad vectors carrying the full-length murine dystrophin cDNA driven by the murine MCK promoter that provides transcriptional targeting for muscle gene delivery of dystrophin. The HC-Ad vectors generated for this study, including the two HC-Ad vectors carrying dystrophin, the HC-Ad vector carrying CTLA4Ig, and the null HC-Ad vector, all share the same DNA backbone with varying amounts of 'stuffer' DNA depending on the size of the therapeutic gene inserts and their promoters. The HC-Ad vector is the only commonly used viral vector for muscle gene delivery that can accommodate the full-length dystrophin cDNA. AdmDys, AdmCTLA4Ig and AdFK0 were each rescued from a single plasmid containing all elements of the HCAd vector genome. In contrast, AdmCTLA4Ig/mDys was generated by cloning the vector genome in two fragments and exploiting homologous recombination within packaging cells to produce the final vector. Both strategies provided acceptable vector yields and purity. Since cloning large plasmids (approximately 30-35 kb) required for the generation of HC-Ad vectors can be difficult to do successfully, the two plasmid strategy used for AdmCTLA4Ig/mDys provides a useful alternative approach. serum. An asterisk (*) marks statistically significant changes in antibody production compared to the AdFK0/AdmDys group in which the adjusted P-value is o0.05 as determined by one-way ANOVA followed by Bonferroni correction for multiple comparisons.
Dystrophin and CTLA4Ig gene transfer to muscle Z Jiang et al
The vector carrying dystrophin alone expressed higher amounts of dystrophin protein than the bicistronic vector carrying both dystrophin and CTLA4Ig when equal amounts of vector were used to infect primary muscle cells in culture. Although we did not test the amount of vector DNA in cells, we expect that it was equivalent since both vectors were packaged with the same helper virus and both vector stocks were quantitated in parallel using the same real-time PCR protocol. The dystrophin gene is driven by the same MCK promoter sequences in both vectors. Therefore, the simplest explanation for the difference in dystrophin expression from the two vectors is that a rearrangement within the vector genome DNA of one vector affected the level of expression, or less likely affected transduction efficiency or vector stability.
We previously demonstrated in vivo that HC-Ad vector-mediated gene delivery of mCTLA4Ig was an effective means of suppressing the immunity that limits gene delivery to muscle with Ad vectors. 20 This encouraging result with marker gene delivery provided the impetus to test Ad vector-mediated gene delivery of mCTLA4Ig in the therapeutic setting of dystrophin delivery to mdx mice. Mdx mice are a genetic and biochemical model of DMD. 22, 23 The genetic absence of the cytoskeletal muscle protein dystrophin results in the secondary loss of the entire dystrophin glycoprotein complex. 24 Dystrophin-deficient muscle fibers are susceptible to contraction-induced injury resulting in recurrent rounds of muscle degeneration and regeneration. In mdx mice, this degenerative process results in variation in muscle fiber size, focal necrosis and regeneration, inflammatory cells and an increasing proportion of fibers harboring centrally placed nuclei reflecting previous regeneration. Previous studies by ourselves and others have demonstrated Ad vectormediated full-length or truncated dystrophin gene delivery to mdx skeletal muscle. [3] [4] [5] [25] [26] [27] [28] [29] [30] [31] [32] Gene delivery of dystrophin to dystrophin-deficient muscle results in restoration of the dystrophin glycoprotein complex and functional benefit. Furthermore, previous studies show that immunosuppression can prolong dystrophin expression from an Ad vector carrying a dystrophin cDNA in mdx muscle. 18, [32] [33] [34] However, this is the first study to combine immunosuppression provided by an immunosuppressant protein gene HC-Ad vector with HC-Ad vector-mediated dystrophin delivery to mdx muscle.
We demonstrated stable expression of dystrophin in skeletal muscle between 2 and 8 weeks after HC-Ad vector administration when dystrophin gene delivery was coupled with CTLA4Ig gene delivery. This was accomplished either by codelivery of two vectors, one carrying the full-length murine dystrophin cDNA and one carrying murine CTLA4Ig or by the delivery of a single bicistronic vector carrying both the murine dystrophin cDNA and murine CTLA4Ig. In contrast to the findings when CTLA4Ig was delivered with dystrophin, dystrophin expression decreased significantly in the control group without CTLA4Ig between the 2-and 8-week time points after AdmDys administration alone. Of note, the experiment was designed to examine the stability of recombinant dystrophin expression in muscle with or without muscle CTLA4Ig expression. The absolute amount of dystrophin transduction in these experiments is relatively low, and would not be expected to be sufficient to produce a therapeutic benefit.
Circulating mCTLA4Ig was present in the serum of all mice that received an IM injection of a vector carrying CTLA4Ig, but not in mice that received the control 'empty' vector, AdFK0. Serum levels of mCTLA4Ig were higher earlier in those mice treated with AdmCTLA4Ig/ mDys compared with those that received a coinjection of AdmCTLA4Ig and AdmDys. This difference was likely due to the higher amount of mCTLA4Ig gene given to the group receiving AdmCTLA4Ig/mDys. Since both strategies resulted in stable dystrophin expression over the time course of the experiment, longer experimental time points would be necessary to explore differences between the codelivery and single bicistronic gene delivery strategies. Although the bicistronic vector approach provides a means to minimize exposure of the gene transfer recipient to Ad capsid proteins, the coinjection approach provides increased flexibility in dosing of the immunosuppressant protein gene vector and mode of delivery (local versus systemic).
Analysis of cellular and humoral immunity suggests that the immunosuppression provided by concomitant CTLA4Ig gene delivery was responsible for the stable dystrophin expression in transduced mdx muscles. CTLA4Ig expression in the setting of HC-Ad vectormediated gene delivery had effects on cytokines released by both Th1 and Th2 CD4 + T cells. Furthermore, we observed suppression of Ad vector stimulated activated CD8 + T cells (CTLs) and anti-Ad neutralizing antibodies produced by B cells. Since gene delivery of CTLA4Ig was by direct injection to skeletal muscle, but CTLA4Ig is a soluble protein that is secreted from muscle into the circulation, we cannot determine whether the effects of CTLA4Ig were predominantly local within treated muscle where the protein was initially expressed or systemic after release of CTLA4Ig into the circulation. We postulate that the principal effects are in the spleen and lymph nodes where CTLA4Ig would be expected to suppress T-cell activation by professional APCs.
The studies reported here demonstrate the utility of a gene delivery approach in a muscular dystrophy disease model using optimal adenoviral vector technology, transcriptional targeting of the dystrophin transgene and vector-mediated immunosuppressant gene delivery. Future studies will be required to address long-term benefit beyond 2 months, to determine optimal dosing and mode of delivery of CTLA4Ig by HC-Ad vectormediated gene transfer and to study the potential for vector readministration in the muscular dystrophy model.
Materials and methods
Cell culture
The 293 (ATCC, Rockville, MD, USA) cell line was propagated at 371C with 5% CO 2 in Dulbecco's minimal essential medium (DMEM) supplemented with 10% (v/v) defined newborn calf serum, penicillin G (100 U/ml), streptomycin (100 mg/ml) and L-glutamine (2%). The 293-based 293Cre4 cell line that expresses Cre protein was propagated in the same media with the addition of 0.4 mg/ml G418. 35 Primary splenocytes were propagated in RPMI1640 medium supplemented with 10% (v/v) FBS, penicillin G (100 U/ml), streptomycin (100 mg/ml) and L-glutamine (2%). Primary myoblasts were isolated Dystrophin and CTLA4Ig gene transfer to muscle Z Jiang et al from mdx skeletal muscle by enzymatic and mechanical dissociation according to a previously published method. 36 Primary myoblasts were propagated in growth medium consisting of Ham's nutrient mixture F-10 supplemented with 20% FBS, 100 U/ml penicillin G, 100 mg/ml streptomycin and 0.25 mg/ml basic fibroblast growth factor. Myoblasts were differentiated into myotubes by changing from growth medium to fusion medium (DMEM supplemented with 2% horse serum).
Generation of vectors DNA cloning. The generation of HC-Ad vectors, AdmCTLA4Ig and AdFK0, was described previously. 20 Toward the generation of HC-Ad vector AdmDys, the vector plasmid pAdSTK122 containing a full-length mouse dystrophin expression cassette was constructed as follows. Plasmid pSTK42 is based on pBluescript and contains the left and right Ad-inverted terminal repeats (ITR) separated by a multiple cloning site. The 14 kb dystrophin cDNA and SV40 polyA+ fragment were inserted into the XhoI site of pSTK42, resulting in pSTK58. The 8.4 kb HPRT stuffer DNA (nt 1777-10227) was inserted into the SalI site of pSTK58, resulting in pSTK123 containing the Ad LITR, HPRT stuffer DNA, murine dystrophin cDNA/pA and Ad RITR. The 6.5 kb muscle creatine kinase (MCK) promoter 37 was inserted into the NotI site between the HPRT stuffer DNA and the dystrophin cDNA of pSTK123, resulting in pSTK122 containing the Ad left ITR, HPRT stuffer DNA, MCK promoter, murine dystrophin cDNA/pA and Ad right ITR (Figure 1) .
The HC-Ad vector, AdmCTLA4Ig/mDys, containing a murine CTLA4Ig expression cassette, HPRT stuffer DNA and murine dystrophin expression cassette, was rescued by homologous recombination of two DNA constructs in 293Cre4 cells. To make the first DNA construct, pCMVb (Invitrogen, Cat. 6177-1) was digested with NotI to release the 3.5 kb LacZ gene and religated, resulting in pCMV that contained the CMV promoter and a polyadenylation signal. A 0.8 kb EcoRI/SalI CMV/ pA fragment was excised from pCMV and subcloned into the EcoRV/StuI site of pSTK68 that contained the Ad left and right ITRs and 16 kb of HPRT stuffer DNA (nt 1777-17853). This resulted in pSTK-CMV that contained the left ITR, CMV/pA, 6.1 kb HPRT stuffer DNA (nt 1799-7900) and right ITR. The NotI-digested mouse CTLA4Ig fragment, excised from pAdmCTLA4Ig, 20 was inserted into the NotI cloning site of CMV promoter of pSTK-CMV, resulting in pSTK-CTLA4Ig. A PmeI/PacIdigested fragment from pSTK-CTLA4Ig containing the Ad left ITR, a murine CTLA4Ig expression cassette and HPRT stuffer DNA was inserted into the PmeI/PacI site of a modified pBR322 plasmid, resulting in pBRCTLA4Ig/HPRT. The 5 0 fragment used for generation of AdmCTLA4Ig/mDys was isolated by PmeI/PacI digestion of pBR-CTLA4Ig/HPRT (Figure 1 ). The 3 0 fragment was released from plasmid pSTK122 by digestion with PmeI and PacI, resulting in a DNA fragment containing 7.1 kb of HPRT intronic sequence, the 6.5 kb MCK promoter, the 14 kb murine dystrophin/ pA sequence and the Ad right ITR. 
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Samples were amplified in 50 ml for 40 cycles in a GeneAmp PCR System 9600 (Perkin Elmer, Norwalk, CT, USA) with continuous fluorescence monitoring. The data were processed using GeneAmp 5700 Sequence Detection System Software (v.11). The plasmids pSTK122 and pBHGE3 (Microbix Inc., Hamilton, Canada) were diluted for making a standard curve. The number of vector copies were calculated according to 1 ng Ad DNA ¼ 3.55 Â 10 7 copies. The concentration of vector was presented as vector gc/ml.
Western blot analysis
For evaluation of transgene protein expression in vitro, myoblasts derived from mdx mouse muscle were infected with HC-Ad vectors and fused into myotubes by changing to fusion media for 5 days. Cell extracts were prepared as described previously. 20 Protein samples (20 mg) were separated on a 10% reducing SDS/PAGE gel for detection of mCTLA4Ig or 5% reducing SDS/PAGE gel for detection of mouse dystrophin. After proteins were transferred to a nitrocellulose membrane, the blots were incubated with a 1:6000 dilution of a biotinylated goat anti-mouse IgG Fc and followed by a 1:500 dilution of HRP-avidin for detection of mCTLA4Ig. Additionally, the blots were incubated with a 1:100 dilution of mouse monoclonal antibody NCL-DYS2 (Novocastra Laboratories Ltd, Newcastle, UK), an antibody directed against the dystrophin carboxy terminal, and followed by a 1:500 dilution of HRP-conjugated sheep anti-mouse IgG for detection of mouse dystrophin protein. The blots were visualized using ECL reagent (Amersham Pharmacia Biotech UK Ltd, UK).
Animal procedures and experimental protocols
The mdx mouse (Jackson Laboratories, Bar Harbor, ME, USA), a dystrophin-deficient mouse model, was used for 
mCTLA4Ig assay
Serum concentration of mCTLA4Ig was assayed by enzyme-linked immunosorbent assay (ELISA) as described previously. 39 Serum levels are expressed as U/ml based on a standard provided by a supernatant from AdmCTLA4Ig-infected HeLa cells because the purified mCTLA4Ig fusion protein corresponding to the DNA carried by the vectors used in this study was not available. An mCTLA4Ig level of 100 U/ml corresponds to the mCTLA4Ig level in 1 ml of a 10 ml supernatant after an overnight infection of 6 Â 10 6 cells with 100 gc/ cell of AdmCTLA4Ig.
Immunohistochemistry assay for mouse dystrophin
Cryostat sections (10 mm) were prepared from the snapfrozen muscle samples. Slides were blocked with PBS containing 10% normal goat serum for 1 h. Subsequently, sections were incubated with primary anti-dystrophin antibody, a sheep polyclonal antibody directed against a C-terminal polypeptide fragment of mouse dystrophin at room temperature for 4-18 h. 21, 40, 41 The secondary antibody, Cy3-conjugated goat anti-sheep polyclonal antibody, was applied for 1 h. The sections were viewed with a Nikon Diaphot fluorescent microscope. The dystrophin-expressing positive fibers were counted and expressed as the average number of positive fibers per muscle cross-section. At least four sections were counted for each muscle.
Splenocyte cytokine assays
Splenocytes were prepared from each harvested spleen by pushing the tissue through a sterile 70 mm nylon cell strainer (Falcon 2350, Lincoln Park, NJ, USA) to generate a single-cell suspension. Splenocytes (1 Â 10 7 cells) were cultured in RPMI1640 with 10% FBS in 24-well plates and either left unstimulated or stimulated with heat-inactivated (651C, 30 min) AdEGFP at an MOI of 10 PFU/cell or UV-treated (20 min) dystrophin-positive myotubes derived from C57BL/10 muscle for 5 days. Cell-free supernatants were collected and analyzed for the presence of mouse IFN-g, mouse IL-2, mouse IL-4 and mouse IL-6 by ELISA. Capture antibody (Pharmingen), detection antibody (Pharmingen) and standard proteins including mouse IL-2 (R&D Systems, Minneapolis, MN, USA), mouse IFN-g, IL-4 and IL-6 (Pharmingen) were diluted according to each manufacturer's protocol. Each assay was repeated at least two times for each sample.
CTL assays
Splenocytes from all mice in each experimental group were pooled and stimulated in vitro with heat-inactivated (651C, 30 min) AdEGFP or UV-treated (20 min) dystrophin-positive C57BL/10 myotubes for 5 days as described above in the Materials and methods section 'Splenocyte cytokine assays'. Target cells for determination of anti-Ad CTL activity were prepared by infecting Mdx myoblasts with AdFK0 that were then fused to form myotubes. Target cells for determination of anti-dystrophin CTL activity were dystrophin-normal C57BL/10 myotubes. Negative control target cells for determination of both anti-Ad and anti-dystrophin CTL were dystrophin-deficient mdx myotubes that were not infected with Ad vector. The target and stimulator cells were treated with 20 U/ml of interferon-g for 10-12 h to upregulate MHC class I expression prior to measuring CTL activity. Using fluorescence-activating cell sorting (FACS), we found that the addition of interferon-g to primary myoblast cultures upregulated MHC class I expression. In preliminary studies we showed that, using these culture conditions, myotubes were acceptable stimulator and target cells in a model assay of MHC class I mismatch (data not shown). CTL activity was measured using a 4-h lactate dehydrogenase (LDH) release assay (CytoTox 96 nonradioactive cytotoxicity assay kit, Promega) using a range of effector to target (E:T) ratios following the manufacturer's instructions. Percentspecific lysis was calculated as (experimentalÀeffector spontaneousÀtarget spontaneous)/(target maximumÀ target spontaneous) Â 100. Each sample was measured in triplicate.
Neutralizing antibody assay
The production of serum neutralizing antibody against Ad vector was assayed by infection of 293 cells with AdEGFP that was incubated with dilutions of mouse serum as described previously. 5, 39 The data are presented as the ratio of fluorescence density from naïve serum to experimental sample. A value of 2 represents 50% inhibition by serum neutralizing antibody against Ad vector.
Statistical analysis
All data are presented as mean7standard error. Differences between mean values of each group were compared by one-way ANOVA, using the Statview program (SAS Institute, Inc., Cary, NC, USA) with the Bonferroni/Dunn correction for multiple comparisons. Differences between mean values were considered statistically significant when adjusted P-values (raw pairwise P-values multiplied by the number of comparisons) were o0.05.
